A Pilot Study of a Grape Seed Procyanidin Extract for Lung Cancer Chemoprevention

• Published in: Cancer prevention research (Philadelphia, Pa.) Vol. 12; no. 8; pp. 557 - 566
• Main Authors: Mao, Jenny T., Lu, Qing-Yi, Xue, Bingye, Neis, Patricia, Zamora, Felix D., Lundmark, Laurie, Qualls, Clifford, Massie, Larry
• Format: Journal Article
• Language: English
• Published: United States 01.08.2019
• Subjects: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - chemistry; Apoptosis; Biflavonoids - administration & dosage; Biflavonoids - adverse effects; Biflavonoids - chemistry; Biopsy; Bronchi - diagnostic imaging; Bronchi - drug effects; Bronchi - pathology; Bronchoscopy; Catechin - administration & dosage; Catechin - adverse effects; Catechin - chemistry; Cell Proliferation; Down-Regulation - drug effects; Female; Gene Expression Regulation, Neoplastic - drug effects; Grape Seed Extract - administration & dosage; Grape Seed Extract - adverse effects; Grape Seed Extract - chemistry; Humans; Ki-67 Antigen - analysis; Ki-67 Antigen - metabolism; Lung Neoplasms - etiology; Lung Neoplasms - genetics; Lung Neoplasms - prevention & control; Male; MicroRNAs - blood; MicroRNAs - metabolism; Middle Aged; Proanthocyanidins - administration & dosage; Proanthocyanidins - adverse effects; Proanthocyanidins - chemistry; Smoking - adverse effects; Treatment Outcome
• ISSN: 1940-6207; 1940-6215; 1940-6215
• DOI: 10.1158/1940-6207.CAPR-19-0053

Grape seed procyanidin extract (GSE) had been reported to exert antineoplastic properties in preclinical studies. A modified phase I, open-label, dose-escalation clinical study was conducted to evaluate the safety, tolerability, MTD, and potential chemopreventive effects of leucoselect phytosome (LP), a standardized GSE complexed with soy phospholipids to enhance bioavailability, in heavy active and former smokers. Eight subjects ages 46–68 years were enrolled into the study and treated with escalating oral doses of LP for 3 months. Bronchoscopies with bronchoalveolar lavage and bronchial biopsies were performed before and after 3 months of LP treatment. Hematoxylin and eosin stain for histopathology grading and IHC examination for Ki-67 proliferative labeling index (Ki-67 LI) were carried out on serially matched bronchial biopsy samples from each subject to determine responses to treatment. Two subjects were withdrawn due to issues unrelated to the study medication, and a total of 6 subjects completed the full study course. In general, 3 months of LP, reaching the highest dose per study protocol was well tolerated and no dosing adjustment was necessary. Such a treatment regimen significantly decreased bronchial Ki-67 LI by an average of 55% (P = 0.041), with concomitant decreases in serum miR-19a, -19b, and -106b, which were oncomirs previously reported to be downregulated by GSE, including LP, in preclinical studies. In spite of not reaching the original enrollment goal of 20, our findings nonetheless support the continued clinical translation of GSE as an antineoplastic and chemopreventive agent against lung cancer.